Abstract
A large amount of data is available on the functional impact of missense mutations in TP53 and on mutation patterns in many different cancers. New data on mutant p53 protein function, cancer phenotype and prognosis have recently been integrated in the International Agency for Research on Cancer TP53 database (http://www-p53.iarc.fr/). Based on these data, we summarize here current knowledge on the respective roles of mutagenesis and biological selection of mutations with specific functional characteristic in shaping the patterns and phenotypes of mutations observed in human cancers. The main conclusion is that intrinsic mutagenicity rates, loss of transactivation activities, and to a lesser extent, dominant-negative activities are the main driving forces that determine TP53 mutation patterns and influence tumor phenotype. In contrast, current experimental data on the acquisition of oncogenic activities (gain of function) by p53 mutants are too scarce and heterogenous to assess whether this property has an impact on tumor development and outcome. In the case of inherited TP53 mutations causing Li–Fraumeni and related syndromes, the age at onset of some tumor types is in direct relation with the degree of loss of transactivation capacity of missense mutations. Finally, studies on large case series demonstrate that TP53 mutations are independent markers of bad prognosis in breast and several other cancers, and that the exact type and position of the mutation influences disease outcome. Further studies are needed to determine how TP53 haplotypes or loss of alleles interact with mutations to modulate their impact on cancer development and prognosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Achatz MI, Olivier M, Calvez FL, Martel-Planche G, Lopes A, Rossi BM et al. (2007). The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett 245: 96–102.
Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A et al. (1994). Is p53 polymorphism maintained by natural selection? Hum Hered 44: 266–270.
Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G et al. (2003). p53 Polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3: 387–402.
Birch JM, Blair V, Kelsey AM, Evans DG, Harris M, Tricker KJ et al. (1998). Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 17: 1061–1068.
Bonafe M, Ceccarelli C, Farabegoli F, Santini D, Taffurelli M, Barbi C et al. (2003). Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res 9: 4860–4864.
Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H et al. (2006). MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66: 5104–5110.
Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC et al. (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591–602.
Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L et al. (2006). Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43: 531–533.
Bougeard G, Brugieres L, Chompret A, Gesta P, Charbonnier F, Valent A et al. (2003). Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene. Oncogene 22: 840–846.
Brachmann RK, Vidal M, Boeke JD . (1996). Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc Natl Acad Sci USA 93: 4091–4095.
Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DA, Pritchard KI et al. (2004). The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol 22: 86–96.
Dearth LR, Qian H, Wang T, Baroni TE, Zeng J, Chen SW et al. (2006). Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis.
Denissenko MF, Pao A, Tang M, Pfeifer GP . (1996). Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 274: 430–432.
DiGiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC et al. (2002). A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol 9: 12–16.
Dumont P, Leu JI, Della III PA, George DL, Murphy M . (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357–365.
Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutierrez-Enriquez S et al. (2004). A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23: 1954–1956.
Hainaut P, Hollstein M . (2000). p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77: 81–137.
Harris SL, Gil G, Hu W, Robins H, Bond E, Hirshfield K et al. (2005). Single-nucleotide polymorphisms in the p53 pathway. Cold Spring Harb Symp Quant Biol 70: 111–119.
Helland A, Langerod A, Johnsen H, Olsen AO, Skovlund E, Borresen-Dale AL . (1998). p53 Polymorphism and risk of cervical cancer [letter]. Nature 396: 530–531.
Hinds PW, Finlay CA, Quartin RS, Baker SJ, Fearon ER, Vogelstein B et al. (1990). Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the ‘hot spot’ mutant phenotypes. Cell Growth Differ 1: 571–580.
Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R et al. (2003). Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100: 8424–8429.
Klug SJ, Wilmotte R, Santos C, Almonte M, Herrero R, Guerrero I et al. (2001). TP53 polymorphism, HPV infection, and risk of cervical cancer. 10: 1009–1012.
Kochethu G, Delgado J, Pepper C, Starczynski J, Hooper L, Krishnan S et al. (2006). Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia. Leuk Res 30: 1113–1118.
Koushik A, Platt RW, Franco EL . (2004). p53 Codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev 13: 11–22.
Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al. (2004). Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861–872.
Langerod A, Bukholm IR, Bregard A, Lonning PE, Andersen TI, Rognum TO et al. (2002). The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 11: 1684–1688.
Langerod A, Burdette L, Yeager M, Llaca V, Presswalla S, Gerhard DS et al. (2006a). Pattern of genetic variation in the tp53 locus indicates linkage disequilibrium extends across the flanking genes, ATP1B2 and WDR79. Hum Mutat (in press).
Langerod A, Zhao H, Borgan O, Nesland JM, Bukholm IK, Ikdahl T et al. (2006b). TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res (in press).
Le Calvez F, Ahman A, Tonisson N, Lambert J, Temam S, Brennan P et al. (2005). Arrayed primer extension resequencing of mutations in the TP53 tumor suppressor gene: comparison with denaturing HPLC and direct sequencing. Clin Chem 51: 1284–1287.
Lunter G, Hein J . (2004). A nucleotide substitution model with nearest-neighbour interactions. Bioinformatics 20 (Suppl 1): I216–I223.
Malkin D, Li FP, Strong LC, Fraumeni JFJ, Nelson CE, Kim DH et al. (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233–1238.
Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA et al. (2000). A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25: 47–54.
Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A et al. (2005). An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102: 13550–13555.
Nelson HH, Wilkojmen M, Marsit CJ, Kelsey KT . (2005). TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis 26: 1770–1773.
Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al. (2004). Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847–860.
Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P . (2002). The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19: 607–614.
Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P et al. (2003). Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63: 6643–6650.
Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J et al. (2006). The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12: 1157–1167.
Ory K, Legros Y, Auguin C, Soussi T . (1994). Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 13: 3496–3504.
Pim D, Banks L . (2004). p53 Polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108: 196–199.
Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR et al. (2001). An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 98: 9330–9335.
Santos AM, Sousa H, Portela C, Pereira D, Pinto D, Catarino R et al. (2006). TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. Biochem Biophys Res Commun 340: 256–262.
Schneider-Stock R, Mawrin C, Motsch C, Boltze C, Peters B, Hartig R et al. (2004). Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am J Pathol 164: 1233–1241.
Siddique M, Sabapathy K . (2006). Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 25: 3489–3500.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869–10874.
Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F et al. (1998). Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393: 229–234.
Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M et al. (2004). Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23: 3328–3337.
Tada M, Furuuchi K, Kaneda M, Matsumoto J, Takahashi M, Hirai A et al. (2001). Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis 22: 515–517.
Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G . (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19: 1092–1100.
Vogelstein B, Lane D, Levine AJ . (2000). Surfing the p53 network. Nature 408: 307–310.
Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M et al. (2004). Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat 24: 21–34.
Wegman P, Stal O, Askmalm MS, Nordenskjold B, Rutqvist LE, Wingren S . (2006). p53 Polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients. Pharmacogenet Genomics 16: 347–351.
Wong P, Verselis SJ, Garber JE, Schneider K, DiGianni L, Stockwell DH et al. (2006). Prevalence of early onset colorectal cancer in 397 patients with classic Li–Fraumeni syndrome. Gastroenterology 130: 73–79.
Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK et al. (2002). p53 Genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 94: 681–690.
Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z et al. (2005). p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 11: 7328–7333.
Zajac V, Tomka M, Ilencikova D, Majek P, Stevurkova V, Kirchhoff T . (2000). A double germline mutations in the APC and p53 genes. Neoplasma 47: 335–341.
Author information
Authors and Affiliations
Corresponding author
Additional information
Links: IARC TP53 database, http://www-p53.iarc.fr/; OMIM TP53, no. 191170; OMIM LFS, no. 151623.
Rights and permissions
About this article
Cite this article
Petitjean, A., Achatz, M., Borresen-Dale, A. et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26, 2157–2165 (2007). https://doi.org/10.1038/sj.onc.1210302
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210302
Keywords
This article is cited by
-
Generation of allogenic chimera carrying mutations in PDX1 and TP53 genes via phytohemagglutinin-mediated blastomere aggregation in pigs
In Vitro Cellular & Developmental Biology - Animal (2024)
-
The expression level of ARF and p53 in AML patients, and their relation to patients' outcome
Egyptian Journal of Medical Human Genetics (2023)
-
Chloroquine induces transitory attenuation of proliferation of human lung cancer cells through regulation of mutant P53 and YAP
Molecular Biology Reports (2023)
-
Whole-exome sequencing reveals mutational profiles of anorectal and gynecological melanoma
Medical Oncology (2023)
-
PO2RDF: representation of real-world data for precision oncology using resource description framework
BMC Medical Genomics (2022)